In this video, Barbara Blodi, MD, discusses the importance of the ellipsoid zone as a biomarker in patients with geographic atrophy.
“There are now AI systems that can measure the ellipsoid zone — its presence or absence or disruption,” Blodi said during a recap about presentations from the ASRS annual meeting.
The FDA recognizes change or loss of the ellipsoid zone (EZ) as an outcome in patients with geographic atrophy (GA), according to Blodi, professor in the department of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health.
“EZ